Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms
Digestive System Diseases
Conditions: official terms
Digestive System Diseases - Digestive System Neoplasms - Gastrointestinal Diseases - Gastrointestinal Neoplasms - Neoplasms
Conditions: Keywords
endoscopic submucosal dissection, gastrointestinal neoplasm
Study Type
Study Phase
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: endoscopic submucosal dissection
Type: Behavioral
Overall Status
Endoscopic submucosal dissection (ESD) is a newly developed technique in the field of endoscopic treatment for GI neoplasms, because of its high rate of en bloc resection. The purpose of this study is to evaluate the efficacy and safety of ESD for GI neoplasms.
Detailed Description
Endoscopic mucosal resection (EMR) is widely accepted as a minimally invasive treatment for GI neoplasms.However, one disadvantage of EMR is that lesions larger than 2 cm in diameter must be removed in pieces, which may result in a high recurrence rate of residual tumor tissue. In addition, in most patients, pathological assessment cannot be conducted after the procedure. ESD can overcome the disadvantages of EMR. However, it is difficult to perform ESD for GI neoplasms because of the high rate of complications.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 90 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Submucosal tumor

- Mucosal tumor (T1) in patients unsuitable for surgery

Exclusion Criteria:

- Endoscopic ultrasound (EUS) or CT signs of metastasis

- Insufficient access to tumor
Chinese PLA General Hospital
Beijing, Beijing, China
Status: Recruiting
Contact: Jin Huang, M.D. - lily712@vip.sina.com
Start Date
January 2009
Completion Date
April 2013
Chinese PLA General Hospital
Chinese PLA General Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page